Latanoprost Sandoz (Latanoprost)

Latanoprost is a prostaglandin F (FP) receptor agonist. Activation of FP receptors on the ciliary body leads to remodeling of the extracellular matrix, which enhances uveoscleral outflow of aqueous humor. The increased outflow reduces intra‑ocular pressure, addressing the primary cause of glaucoma progression.

The dosing regimen is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily, often in the evening, but the exact schedule should follow the prescriber’s instructions.

Safety data for Latanoprost during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

Enquiries can be submitted on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

The primary alternative class is beta‑blocker eye drops such as timolol. While beta‑blockers reduce aqueous humor production, latanoprost increases uveoscleral outflow. Latanoprost often provides greater pressure reduction with once‑daily dosing, but beta‑blockers may be preferred in patients with contraindications to prostaglandins.

Store the ophthalmic solution at room temperature, below 25 °C, in the original container. Protect the bottle from direct light and moisture, and keep the tip clean to avoid contamination. Do not freeze the product.

Instill one drop into the prescribed eye(s) using the provided dropper. The drop should be placed on the lower conjunctival sac without touching the tip to the ocular surface. Patients are usually advised to administer the drop in the evening and to avoid blinking excessively for a few minutes.

Serious but rare risks include severe allergic reactions, uveitis, macular edema, paradoxical increase in intra‑ocular pressure, and corneal edema. Patients should seek immediate medical attention if they experience sudden vision loss, severe eye pain, redness, or signs of infection.

Latanoprost should be avoided in individuals with active ocular inflammation, known hypersensitivity to latanoprost or any component of the formulation, and in patients who have experienced severe adverse reactions to prostaglandin analogs. Contraindications must be confirmed by the prescribing clinician.